These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 7796949)

  • 1. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.
    Paoletti E; Taylor J; Meignier B; Meric C; Tartaglia J
    Dev Biol Stand; 1995; 84():159-63. PubMed ID: 7796949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safe and effective poxvirus vectors--NYVAC and ALVAC.
    Paoletti E; Tartaglia J; Taylor J
    Dev Biol Stand; 1994; 82():65-9. PubMed ID: 7958484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs.
    Kyriakis CS; De Vleeschauwer A; Barbé F; Bublot M; Van Reeth K
    Vaccine; 2009 Apr; 27(16):2258-64. PubMed ID: 19428840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poxvirus-based vectors as vaccine candidates.
    Pincus S; Tartaglia J; Paoletti E
    Biologicals; 1995 Jun; 23(2):159-64. PubMed ID: 7546658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein.
    Cox WI; Tartaglia J; Paoletti E
    Virology; 1993 Aug; 195(2):845-50. PubMed ID: 8337851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines.
    Welter J; Taylor J; Tartaglia J; Paoletti E; Stephensen CB
    J Virol; 2000 Jul; 74(14):6358-67. PubMed ID: 10864646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans.
    Kanesa-thasan N; Smucny JJ; Hoke CH; Marks DH; Konishi E; Kurane I; Tang DB; Vaughn DW; Mason PW; Shope RE
    Vaccine; 2000 Oct; 19(4-5):483-91. PubMed ID: 11027812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing poxvirus vectors vaccine immunogenicity.
    García-Arriaza J; Esteban M
    Hum Vaccin Immunother; 2014; 10(8):2235-44. PubMed ID: 25424927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus.
    Sutter G; Moss B
    Dev Biol Stand; 1995; 84():195-200. PubMed ID: 7796954
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC.
    Tartaglia J; Cox WI; Pincus S; Paoletti E
    Dev Biol Stand; 1994; 82():125-9. PubMed ID: 7958466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.
    Taylor J; Paoletti E
    Prog Vet Microbiol Immunol; 1988; 4():197-217. PubMed ID: 3078866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of canarypox (ALVAC) vectors in human and veterinary vaccination.
    Taylor J; Tartaglia J; Rivière M; Duret C; Languet B; Chappuis G; Paoletti E
    Dev Biol Stand; 1994; 82():131-5. PubMed ID: 7958467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of vaccine vectors.
    Dorner F
    Dev Biol Stand; 1995; 84():23-32. PubMed ID: 7796959
    [No Abstract]   [Full Text] [Related]  

  • 15. The safety and use of canarypox vectored vaccines.
    Plotkin SA; Cadoz M; Meignier B; Méric C; Leroy O; Excler JL; Tartaglia J; Paoletti E; Gonczol E; Chappuis G
    Dev Biol Stand; 1995; 84():165-70. PubMed ID: 7796950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poxvirus-based Japanese encephalitis vaccine candidates induce JE virus-specific CD8+ cytotoxic T lymphocytes in mice.
    Konishi E; Kurane I; Mason PW; Shope RE; Ennis FA
    Virology; 1997 Jan; 227(2):353-60. PubMed ID: 9018134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poxviruses as vaccine vectors.
    Pastoret PP; Vanderplasschen A
    Comp Immunol Microbiol Infect Dis; 2003 Oct; 26(5-6):343-55. PubMed ID: 12818621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safe and effective use of fowlpox virus as a vector for poultry vaccines.
    McMillen JK; Cochran MD; Junker DE; Reddy DN; Valencia DM
    Dev Biol Stand; 1994; 82():137-45. PubMed ID: 7958468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A chemically defined production process for highly attenuated poxviruses.
    Jordan I; Northoff S; Thiele M; Hartmann S; Horn D; Höwing K; Bernhardt H; Oehmke S; von Horsten H; Rebeski D; Hinrichsen L; Zelnik V; Mueller W; Sandig V
    Biologicals; 2011 Jan; 39(1):50-8. PubMed ID: 21237672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2).
    Jourdier TM; Moste C; Bonnet MC; Delisle F; Tafani JP; Devauchelle P; Tartaglia J; Moingeon P
    Gene Ther; 2003 Dec; 10(26):2126-32. PubMed ID: 14625567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.